Author

J. Volkov

Observed names: Jenell R. Volkov, Jenell Volkov

OpenAlex ID: A5108294341

Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I/II trial

2024 · Jenell Volkov, Daniel Nunez, et al. · Molecular Therapy · 54

Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy

2023 · Daniel Nunez, Darshil Patel, et al. · Molecular Therapy — Methods & Clinical Development · 50

Op0202 Reset-sle: Clinical Trial Evaluating Rese-cel (resecabtagene Autoleucel), a Fully Human, Autologous 4-1bb Anti-cd19 Car T Cell Therapy in Non-renal Sle and Lupus Nephritis

2025 · S. Sheikh, V. Derebail, et al. · Annals of the Rheumatic Diseases · 9

LB952 A phase 1 trial of DSG3-CAART cells in mucosal-dominant pemphigus vulgaris (mPV) patients: Preliminary data

2022 · D.J. Chang, S. Basu, et al. · Journal of Investigative Dermatology · 8

CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial

2026 · Daniel Nunez, Jason Stadanlick, et al. · Blood · 4

OP0338 RESET-SScTM: CLINICAL TRIAL EVALUATING Rese-cel (RESECABTAGENE AUTOLEUCEL), A FULLY HUMAN, AUTOLOGOUS 4-1BB ANTI-CD19 CAR T CELL THERAPY IN SYSTEMIC SCLEROSIS

2025 · D. Khanna, M. Ghosh, et al. · Annals of the Rheumatic Diseases · 4

OP0316 RESET-MYOSITISTM: CLINICAL TRIAL EVALUATING Rese-cel (RESECABTAGENE AUTOLEUCEL), A FULLY HUMAN, AUTOLOGOUS 4-1BB ANTI-CD19 CAR T CELL THERAPY IN IDIOPATHIC INFLAMMATORY MYOPATHIES

2025 · T. Mozaffar, E. Naddaf, et al. · Annals of the Rheumatic Diseases · 3

Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial

2025 · Daniel Nunez, Jenell R. Volkov, et al. · Molecular Therapy Advances · 2

0434 Clinical and translational data from a first-in-human study of a novel precision cellular immunotherapy (DSG3-CAART) in mucosal pemphigus vulgaris

2025 · A.S. Payne, D. Nunez, et al. · Journal of Investigative Dermatology · 2

Reset Sle: Clinical Trial Evaluating Caba-201, a Fully Human, Autologous 4-1bb Anti-cd19 Car T Cell Therapy in Nonrenal Sle and Lupus Nephritis

2025 · Saira Sheikh, Vimal Derebail, et al. · The Journal of Rheumatology · 2

RESET-MG: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB-CD19-CAR T Cell Therapy in Generalized Myasthenia Gravis (gMG) (S14.003)

2026 · Ali Habib, Stefan Ciurea, et al. · Neurology

P.257 Reset-SSc: clinical trial evaluating rese-cel (resecabtagene autoleucel), a fully human, autologous 4-1BB CD19-CAR T cell therapy in systemic sclerosis

2026 · Dinesh Khanna, Monalisa Ghosh, et al. · Poster presentations

PO:11:274 RESET SLE: clinical trial evaluating rese-cel (resecabtagene autoleucel), a fully human, autologous 4–1BB anti-CD19 CAR T cell therapy in non-renal SLE and lupus nephritis (LN)

2026 · Saira Sheikh, Vimal Derebail, et al.

Mechanistic basis of the acute safety profile of rese-cel, an autologous CD19-CAR T, in patients with autoimmune disease treated in four ongoing phase 1/2 clinical trials

2025 · Daniel Nunez, Jenell Volkov, et al. · Blood

Works count: 14

Citation count: 138

H-index: 4

I10-index: 2